DuChemBIO Co.,Ltd. (KOSDAQ:176750)

South Korea · Delayed Price · Currency is KRW

6,020.00

+50.00 (0.84%)

At close: Jul 16, 2026

-40.16% (1Y)

Market Cap	170.64B -42.3%
Revenue (ttm)	39.82B +11.7%
Net Income	6.97B -8.3%
EPS	246.97 -10.9%
Shares Out	28.34M
PE Ratio	24.38
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,278
Open	5,980.00
Previous Close	5,970.00
Day's Range	5,770.00 - 6,080.00
52-Week Range	5,530.00 - 12,770.00
Beta	0.04
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 13, 2026

About DuChemBIO

DuChemBIO Co.,Ltd. engages in the development, production, and sale of radiopharmaceutical products for cancer diagnosis and treatment in South Korea. Its products include FP-CIT for diagnosis of Parkinson’s disease and Parkinson's syndrome by measuring the density of dopamine transporters present in the brain striatum; F-DOPA for brain tumor diagnosis with neutralization technology; Neuraceq for diagnosis of Alzheimer's disease by measuring the distribution and density of beta amyloid in the brain; and Vizamyl for early diagnosis of beta amylo... [Read more]

Industry Orthopedic, Prosthetic, and Surgical Appliances and Supplies

Founded 2002

Employees 126

Stock Exchange KOSDAQ

Ticker Symbol 176750

Full Company Profile

Financial Performance

In 2025, DuChemBIO's revenue was 38.57 billion, an increase of 8.35% compared to the previous year's 35.60 billion. Earnings were 6.48 billion, a decrease of -18.94%.

Financial Statements